Archive

Browse through all of our previously written posts.

Free Newsletter

The healthspan market is becoming buyable

Premium prevention, reprogramming capital, a first-human epigenetic-restoration trial, insurance-supported women's midlife care, and Medicare access rules are turning longevity from aspiration into products, proof, payment, and buyer behavior.

Aug 18, 2026

•

8 min read

The channel decides what scales

Blood draws, insurer pathways, lab reimbursement, artificial-intelligence screening workflows, and employer benefits show why healthspan businesses scale through access points as much as better tests.

Aug 25, 2026

•

8 min read

The platforms hit their commercial tests

Artificial-intelligence drug discovery, gene editing, cancer screening, and aging-biology companies now face the same test: can they turn technology into products that buyers, regulators, clinicians, and payers will act on?

Sep 1, 2026

•

7 min read

Deep Dives

Money and motivation

Concierge doctors help drive longevity movement

Aug 18, 2026

•

4 min read

Can NAD+ precursors remain the hot longevity ingredient?

Supplement brands in the NAD+ space deploy innovation and science to maintain consumer interest